Biogen, UCB detail response rates in Phase 3 lupus study Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 19 November, 2024

John Carroll talks to industry execs about the FDA, the new guard, funding and more — how are they planning for 2025? Tune in — register today.

presented by Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

news Merck finally has subcutaneous Keytruda results, and it's going to regulators Incyte’s bet on Escient hits a snag as safety issues hamper Phase 2 chronic hives trial Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success Vir, Bluejay invigorate hepatitis D landscape with new data

Nov 19 11:00am ET Gene therapy assays: Achieving regulatory compliance with a unified immunogenicity strategy sponsored by Precision for Medicine Dec 03 12:30pm ET From AI to IRA to GLP-1s: Unpacking the major healthcare trends at #JPM2025 sponsored by Real Chemistry Dec 04 12:00pm ET The pragmatic shift: Designing trials that fit the real world sponsored by Flatiron Dec 09 1:00pm ET Accelerating drug discovery with an end-to-end imaging data management platform sponsored by Flywheel Dec 12 11:00am ET Accelerating discovery in targeted protein degradation: Innovative approaches to degrader screening sponsored by Bio Techne

Biopharma’s elite are descending upon JPM, and our event is your insider’s guide to the industry. Join conversations with dealmakers, investors, and industry titans. The Endpoints Hub is your oasis amidst the JPM frenzy. Secure your spot now — Early Bird is ending soon.

endoints pharma Rocket shares promising long-term results from rare heart disease gene therapy in small study FDA offers more guidance on developing cell and gene therapies Neurogene patient had life-threatening side effect in Rett syndrome study Syndax's Revuforj wins FDA approval in aggressive form of leukemia

in case you missed it 1. In Focus A rare neurological disease is Sage’s last, best hope after failures in depression 2. Novartis strikes radiopharma deal with Ratio worth up to $745M 3. Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset 4. Scottish biotech debuts with ‘Trojan horse’ platform for cancer 5. Eisai terminates Phase 3 trial of